Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

A Phase 1b/2, open-label, multicenter study to determine the recommended phase 2 (RP2D) of ABT-101in solid tumor and to explore antitumor activities of ABT-101 in patients with HER 2 mutated non-small cell lung cancer (NSCLC)

Trial Details

NCT ID
NCT05532696
Phase
PHASE1 / PHASE2
Sponsor
Anbogen Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • ABT-101
Locations (sample)
  • Taichung, Taiwan|24.1469,120.6839
  • Tainan, Taiwan|22.99083,120.21333
  • Taipei, Taiwan|25.05306,121.52639
  • Taipei, Taiwan|25.05306,121.52639
  • Taoyuan District, Taiwan|24.9896,121.3187

Key Eligibility Criteria

  • Male or female aged ≥ 20 years or adult age as per local regulations, at time of informed consent
  • Histologically or cytologically confirmed advanced solid tumor (Part 1) or NSCLC with HER2 mutations as determined by the central result (Part 2)
  • For patients in Part 2 only: Patients has measurable disease per RECIST 1.1 criteria
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Part 1), 0 to 2 (Part 2)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →